Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
17 hedge funds and large institutions have $16.3M invested in Calliditas Therapeutics AB American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more capital invested
Capital invested by funds: $13.9M → $16.3M (+$2.42M)
6% more funds holding
Funds holding: 16 → 17 (+1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
90% less call options, than puts
Call options by funds: $50K | Put options by funds: $522K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$205K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$65.8K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$7.79K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7.63K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
-$79K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$10.4K |
| 3 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
-$9.1K |
| 4 |
Morgan Stanley
New York
|
-$5.67K |
| 5 |
JP Morgan Chase
New York
|
-$3.15K |
CALT Hedge Fund Activity: Q3 2023 in Review
17 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q3 2023, worth a combined $16.3M — up 17% from $13.9M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CALT positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $205K. The largest seller was Optiver Holding, exiting entirely with an estimated $79K sold.
- 17 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q3 2023, up from 16 in Q2 2023.
- Funds reported $16.3M of Calliditas Therapeutics AB American Depositary Shares stock for Q3 2023, up 17% quarter-over-quarter.
- 2 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q3 2023 was Sphera Funds Management, an estimated $205K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q3 2023 was Optiver Holding, an estimated $79K sold.
Based on aggregated 13F filings for Q3 2023.